ZOLL Medical Beats Up on Analysts Yet Again
ZOLL Medical (NAS: ZOLL) reported earnings on Jan. 19. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Jan. 1 (Q1), ZOLL Medical met expectations on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly, and earnings per share increased significantly.
Margins improved across the board.
ZOLL Medical booked revenue of $134 million. The eight analysts polled by S&P Capital IQ foresaw net sales of $133 million. Sales were 18% higher than the prior-year quarter's $113 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
EPS came in at $0.29. The five earnings estimates compiled by S&P Capital IQ predicted $0.27 per share. GAAP EPS of $0.29 for Q1 were 61% higher than the prior-year quarter's $0.18 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 58.7%, 450 basis points better than the prior-year quarter. Operating margin was 7.9%, 320 basis points better than the prior-year quarter. Net margin was 5.0%, 160 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $147 million. On the bottom line, the average EPS estimate is $0.38.
Next year's average estimate for revenue is $616 million. The average EPS estimate is $1.95.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 141 members out of 150 rating the stock outperform, and nine members rating it underperform. Among 53 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give ZOLL Medical a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ZOLL Medical is outperform, with an average price target of $73.13.
The healthcare investing landscape is littered with also-rans and a few major winners. Is ZOLL Medical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Motley Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add ZOLL Medical to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.